Browse CCL5

Summary
SymbolCCL5
Namechemokine (C-C motif) ligand 5
Aliases RANTES; SISd; TCP228; MGC17164; T-cell specific protein p288; T-cell specific RANTES protein; SIS-delta; reg ......
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted.
Domain PF00048 Small cytokines (intecrine/chemokine)
Function

Chemoattractant for blood monocytes, memory T-helper cells and eosinophils. Causes the release of histamine from basophils and activates eosinophils. May activate several chemokine receptors including CCR1, CCR3, CCR4 and CCR5. One of the major HIV-suppressive factors produced by CD8+ T-cells. Recombinant RANTES protein induces a dose-dependent inhibition of different strains of HIV-1, HIV-2, and simian immunodeficiency virus (SIV). The processed form RANTES(3-68) acts as a natural chemotaxis inhibitor and is a more potent inhibitor of HIV-1-infection. The second processed form RANTES(4-68) exhibits reduced chemotactic and HIV-suppressive activity compared with RANTES(1-68) and RANTES(3-68) and is generated by an unidentified enzyme associated with monocytes and neutrophils (PubMed:16791620, PubMed:1380064, PubMed:8525373, PubMed:9516414, PubMed:15923218). May also be an agonist of the G protein-coupled receptor GPR75, stimulating inositol trisphosphate production and calcium mobilization through its activation. Together with GPR75, may play a role in neuron survival through activation of a downstream signaling pathway involving the PI3, Akt and MAP kinases. By activating GPR75 may also play a role in insulin secretion by islet cells (PubMed:23979485).

> Gene Ontology
 
Biological Process GO:0001959 regulation of cytokine-mediated signaling pathway
GO:0001960 negative regulation of cytokine-mediated signaling pathway
GO:0002237 response to molecule of bacterial origin
GO:0002274 myeloid leukocyte activation
GO:0002407 dendritic cell chemotaxis
GO:0002544 chronic inflammatory response
GO:0002548 monocyte chemotaxis
GO:0002676 regulation of chronic inflammatory response
GO:0002685 regulation of leukocyte migration
GO:0002687 positive regulation of leukocyte migration
GO:0002688 regulation of leukocyte chemotaxis
GO:0002690 positive regulation of leukocyte chemotaxis
GO:0002694 regulation of leukocyte activation
GO:0002696 positive regulation of leukocyte activation
GO:0002790 peptide secretion
GO:0002791 regulation of peptide secretion
GO:0006413 translational initiation
GO:0006417 regulation of translation
GO:0006446 regulation of translational initiation
GO:0006816 calcium ion transport
GO:0006874 cellular calcium ion homeostasis
GO:0006875 cellular metal ion homeostasis
GO:0006887 exocytosis
GO:0006925 inflammatory cell apoptotic process
GO:0007159 leukocyte cell-cell adhesion
GO:0007259 JAK-STAT cascade
GO:0007260 tyrosine phosphorylation of STAT protein
GO:0008277 regulation of G-protein coupled receptor protein signaling pathway
GO:0009306 protein secretion
GO:0009615 response to virus
GO:0009636 response to toxic substance
GO:0009914 hormone transport
GO:0010517 regulation of phospholipase activity
GO:0010518 positive regulation of phospholipase activity
GO:0010533 regulation of activation of Janus kinase activity
GO:0010534 regulation of activation of JAK2 kinase activity
GO:0010535 positive regulation of activation of JAK2 kinase activity
GO:0010536 positive regulation of activation of Janus kinase activity
GO:0010608 posttranscriptional regulation of gene expression
GO:0010758 regulation of macrophage chemotaxis
GO:0010759 positive regulation of macrophage chemotaxis
GO:0010817 regulation of hormone levels
GO:0010818 T cell chemotaxis
GO:0010819 regulation of T cell chemotaxis
GO:0010820 positive regulation of T cell chemotaxis
GO:0010959 regulation of metal ion transport
GO:0014065 phosphatidylinositol 3-kinase signaling
GO:0014066 regulation of phosphatidylinositol 3-kinase signaling
GO:0014068 positive regulation of phosphatidylinositol 3-kinase signaling
GO:0014812 muscle cell migration
GO:0014909 smooth muscle cell migration
GO:0014910 regulation of smooth muscle cell migration
GO:0014911 positive regulation of smooth muscle cell migration
GO:0015833 peptide transport
GO:0018108 peptidyl-tyrosine phosphorylation
GO:0018212 peptidyl-tyrosine modification
GO:0019058 viral life cycle
GO:0019079 viral genome replication
GO:0019080 viral gene expression
GO:0019083 viral transcription
GO:0022407 regulation of cell-cell adhesion
GO:0022409 positive regulation of cell-cell adhesion
GO:0023061 signal release
GO:0030072 peptide hormone secretion
GO:0030073 insulin secretion
GO:0030335 positive regulation of cell migration
GO:0030593 neutrophil chemotaxis
GO:0030595 leukocyte chemotaxis
GO:0031349 positive regulation of defense response
GO:0031584 activation of phospholipase D activity
GO:0031663 lipopolysaccharide-mediated signaling pathway
GO:0032103 positive regulation of response to external stimulus
GO:0032147 activation of protein kinase activity
GO:0032496 response to lipopolysaccharide
GO:0032897 negative regulation of viral transcription
GO:0032943 mononuclear cell proliferation
GO:0032944 regulation of mononuclear cell proliferation
GO:0032946 positive regulation of mononuclear cell proliferation
GO:0033002 muscle cell proliferation
GO:0033028 myeloid cell apoptotic process
GO:0033032 regulation of myeloid cell apoptotic process
GO:0033033 negative regulation of myeloid cell apoptotic process
GO:0033627 cell adhesion mediated by integrin
GO:0033628 regulation of cell adhesion mediated by integrin
GO:0033630 positive regulation of cell adhesion mediated by integrin
GO:0033631 cell-cell adhesion mediated by integrin
GO:0033632 regulation of cell-cell adhesion mediated by integrin
GO:0033634 positive regulation of cell-cell adhesion mediated by integrin
GO:0033674 positive regulation of kinase activity
GO:0034109 homotypic cell-cell adhesion
GO:0034110 regulation of homotypic cell-cell adhesion
GO:0034112 positive regulation of homotypic cell-cell adhesion
GO:0034248 regulation of cellular amide metabolic process
GO:0034250 positive regulation of cellular amide metabolic process
GO:0034341 response to interferon-gamma
GO:0034612 response to tumor necrosis factor
GO:0035747 natural killer cell chemotaxis
GO:0035821 modification of morphology or physiology of other organism
GO:0036230 granulocyte activation
GO:0036336 dendritic cell migration
GO:0040017 positive regulation of locomotion
GO:0042098 T cell proliferation
GO:0042102 positive regulation of T cell proliferation
GO:0042110 T cell activation
GO:0042119 neutrophil activation
GO:0042129 regulation of T cell proliferation
GO:0042509 regulation of tyrosine phosphorylation of STAT protein
GO:0042531 positive regulation of tyrosine phosphorylation of STAT protein
GO:0042886 amide transport
GO:0042976 activation of Janus kinase activity
GO:0042977 activation of JAK2 kinase activity
GO:0043270 positive regulation of ion transport
GO:0043410 positive regulation of MAPK cascade
GO:0043491 protein kinase B signaling
GO:0043900 regulation of multi-organism process
GO:0043901 negative regulation of multi-organism process
GO:0043902 positive regulation of multi-organism process
GO:0043903 regulation of symbiosis, encompassing mutualism through parasitism
GO:0043921 modulation by host of viral transcription
GO:0043922 negative regulation by host of viral transcription
GO:0044033 multi-organism metabolic process
GO:0044344 cellular response to fibroblast growth factor stimulus
GO:0045069 regulation of viral genome replication
GO:0045070 positive regulation of viral genome replication
GO:0045071 negative regulation of viral genome replication
GO:0045088 regulation of innate immune response
GO:0045089 positive regulation of innate immune response
GO:0045727 positive regulation of translation
GO:0045744 negative regulation of G-protein coupled receptor protein signaling pathway
GO:0045785 positive regulation of cell adhesion
GO:0045860 positive regulation of protein kinase activity
GO:0045948 positive regulation of translational initiation
GO:0046425 regulation of JAK-STAT cascade
GO:0046427 positive regulation of JAK-STAT cascade
GO:0046651 lymphocyte proliferation
GO:0046782 regulation of viral transcription
GO:0046879 hormone secretion
GO:0046883 regulation of hormone secretion
GO:0048015 phosphatidylinositol-mediated signaling
GO:0048017 inositol lipid-mediated signaling
GO:0048245 eosinophil chemotaxis
GO:0048246 macrophage chemotaxis
GO:0048247 lymphocyte chemotaxis
GO:0048524 positive regulation of viral process
GO:0048525 negative regulation of viral process
GO:0048659 smooth muscle cell proliferation
GO:0048660 regulation of smooth muscle cell proliferation
GO:0048661 positive regulation of smooth muscle cell proliferation
GO:0050670 regulation of lymphocyte proliferation
GO:0050671 positive regulation of lymphocyte proliferation
GO:0050673 epithelial cell proliferation
GO:0050678 regulation of epithelial cell proliferation
GO:0050679 positive regulation of epithelial cell proliferation
GO:0050708 regulation of protein secretion
GO:0050727 regulation of inflammatory response
GO:0050729 positive regulation of inflammatory response
GO:0050730 regulation of peptidyl-tyrosine phosphorylation
GO:0050731 positive regulation of peptidyl-tyrosine phosphorylation
GO:0050792 regulation of viral process
GO:0050796 regulation of insulin secretion
GO:0050863 regulation of T cell activation
GO:0050865 regulation of cell activation
GO:0050867 positive regulation of cell activation
GO:0050870 positive regulation of T cell activation
GO:0050900 leukocyte migration
GO:0050918 positive chemotaxis
GO:0050920 regulation of chemotaxis
GO:0050921 positive regulation of chemotaxis
GO:0051249 regulation of lymphocyte activation
GO:0051251 positive regulation of lymphocyte activation
GO:0051259 protein oligomerization
GO:0051262 protein tetramerization
GO:0051272 positive regulation of cellular component movement
GO:0051702 interaction with symbiont
GO:0051817 modification of morphology or physiology of other organism involved in symbiotic interaction
GO:0051851 modification by host of symbiont morphology or physiology
GO:0051924 regulation of calcium ion transport
GO:0051928 positive regulation of calcium ion transport
GO:0052312 modulation of transcription in other organism involved in symbiotic interaction
GO:0052472 modulation by host of symbiont transcription
GO:0055074 calcium ion homeostasis
GO:0060191 regulation of lipase activity
GO:0060193 positive regulation of lipase activity
GO:0060326 cell chemotaxis
GO:0060759 regulation of response to cytokine stimulus
GO:0060761 negative regulation of response to cytokine stimulus
GO:0061097 regulation of protein tyrosine kinase activity
GO:0061098 positive regulation of protein tyrosine kinase activity
GO:0070098 chemokine-mediated signaling pathway
GO:0070099 regulation of chemokine-mediated signaling pathway
GO:0070100 negative regulation of chemokine-mediated signaling pathway
GO:0070227 lymphocyte apoptotic process
GO:0070228 regulation of lymphocyte apoptotic process
GO:0070229 negative regulation of lymphocyte apoptotic process
GO:0070230 positive regulation of lymphocyte apoptotic process
GO:0070231 T cell apoptotic process
GO:0070232 regulation of T cell apoptotic process
GO:0070233 negative regulation of T cell apoptotic process
GO:0070234 positive regulation of T cell apoptotic process
GO:0070371 ERK1 and ERK2 cascade
GO:0070372 regulation of ERK1 and ERK2 cascade
GO:0070374 positive regulation of ERK1 and ERK2 cascade
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0070555 response to interleukin-1
GO:0070661 leukocyte proliferation
GO:0070663 regulation of leukocyte proliferation
GO:0070665 positive regulation of leukocyte proliferation
GO:0070838 divalent metal ion transport
GO:0070997 neuron death
GO:0071216 cellular response to biotic stimulus
GO:0071219 cellular response to molecule of bacterial origin
GO:0071222 cellular response to lipopolysaccharide
GO:0071346 cellular response to interferon-gamma
GO:0071347 cellular response to interleukin-1
GO:0071356 cellular response to tumor necrosis factor
GO:0071396 cellular response to lipid
GO:0071407 cellular response to organic cyclic compound
GO:0071593 lymphocyte aggregation
GO:0071621 granulocyte chemotaxis
GO:0071622 regulation of granulocyte chemotaxis
GO:0071674 mononuclear cell migration
GO:0071675 regulation of mononuclear cell migration
GO:0071677 positive regulation of mononuclear cell migration
GO:0071774 response to fibroblast growth factor
GO:0071887 leukocyte apoptotic process
GO:0071888 macrophage apoptotic process
GO:0072503 cellular divalent inorganic cation homeostasis
GO:0072507 divalent inorganic cation homeostasis
GO:0072511 divalent inorganic cation transport
GO:0072676 lymphocyte migration
GO:0072677 eosinophil migration
GO:0072678 T cell migration
GO:0090025 regulation of monocyte chemotaxis
GO:0090026 positive regulation of monocyte chemotaxis
GO:0090087 regulation of peptide transport
GO:0090276 regulation of peptide hormone secretion
GO:0097529 myeloid leukocyte migration
GO:0097530 granulocyte migration
GO:0097696 STAT cascade
GO:1901214 regulation of neuron death
GO:1901623 regulation of lymphocyte chemotaxis
GO:1903037 regulation of leukocyte cell-cell adhesion
GO:1903039 positive regulation of leukocyte cell-cell adhesion
GO:1903900 regulation of viral life cycle
GO:1903901 negative regulation of viral life cycle
GO:1903902 positive regulation of viral life cycle
GO:1904892 regulation of STAT cascade
GO:1904894 positive regulation of STAT cascade
GO:1990266 neutrophil migration
GO:2000106 regulation of leukocyte apoptotic process
GO:2000107 negative regulation of leukocyte apoptotic process
GO:2000108 positive regulation of leukocyte apoptotic process
GO:2000109 regulation of macrophage apoptotic process
GO:2000110 negative regulation of macrophage apoptotic process
GO:2000147 positive regulation of cell motility
GO:2000401 regulation of lymphocyte migration
GO:2000403 positive regulation of lymphocyte migration
GO:2000404 regulation of T cell migration
GO:2000406 positive regulation of T cell migration
GO:2000501 regulation of natural killer cell chemotaxis
GO:2000503 positive regulation of natural killer cell chemotaxis
Molecular Function GO:0001664 G-protein coupled receptor binding
GO:0004435 phosphatidylinositol phospholipase C activity
GO:0004620 phospholipase activity
GO:0004629 phospholipase C activity
GO:0005125 cytokine activity
GO:0005126 cytokine receptor binding
GO:0008009 chemokine activity
GO:0008047 enzyme activator activity
GO:0008081 phosphoric diester hydrolase activity
GO:0016004 phospholipase activator activity
GO:0016298 lipase activity
GO:0019207 kinase regulator activity
GO:0019209 kinase activator activity
GO:0019887 protein kinase regulator activity
GO:0030295 protein kinase activator activity
GO:0030296 protein tyrosine kinase activator activity
GO:0030298 receptor signaling protein tyrosine kinase activator activity
GO:0030545 receptor regulator activity
GO:0030547 receptor inhibitor activity
GO:0031726 CCR1 chemokine receptor binding
GO:0031729 CCR4 chemokine receptor binding
GO:0031730 CCR5 chemokine receptor binding
GO:0042056 chemoattractant activity
GO:0042379 chemokine receptor binding
GO:0042578 phosphoric ester hydrolase activity
GO:0043621 protein self-association
GO:0046817 chemokine receptor antagonist activity
GO:0048019 receptor antagonist activity
GO:0048020 CCR chemokine receptor binding
GO:0060229 lipase activator activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04060 Cytokine-cytokine receptor interaction
hsa04062 Chemokine signaling pathway
hsa04620 Toll-like receptor signaling pathway
hsa04621 NOD-like receptor signaling pathway
hsa04623 Cytosolic DNA-sensing pathway
hsa04668 TNF signaling pathway
Reactome R-HSA-380108: Chemokine receptors bind chemokines
R-HSA-373076: Class A/1 (Rhodopsin-like receptors)
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-418594: G alpha (i) signalling events
R-HSA-388396: GPCR downstream signaling
R-HSA-500792: GPCR ligand binding
R-HSA-168256: Immune System
R-HSA-6783783: Interleukin-10 signaling
R-HSA-375276: Peptide ligand-binding receptors
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
R-HSA-449147: Signaling by Interleukins
Summary
SymbolCCL5
Namechemokine (C-C motif) ligand 5
Aliases RANTES; SISd; TCP228; MGC17164; T-cell specific protein p288; T-cell specific RANTES protein; SIS-delta; reg ......
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CCL5 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between CCL5 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
26729864MelanomaPromote immunityVaccination with combination therapy uniquely restricted Th2-cytokine production by CD4 cells, relative to combination therapy alone, and enhanced IFNγ production by CD8 and CD4 cells. We observed an increase in MIP-1α (macrophage inflammatory protein-1α)/CCL3 [chemokine (C-C motif) ligand 3], MIP-1β/CCL4, RANTES (regulated on activation, normal T-cell expressed and excreted)/CCL5, and GM-CSF production by CD8 and CD4 T cells following treatment.
26719346MelanomaPromote immunity (infiltration)Senescent melanoma cells secret CCL5, which promotes recruitment of TILs.
26719303Colorectal CarcinomaPromote immunity (infiltration)Indeed, owing to IL-17 secretion, CRC-derived Th17 triggered the release of protumorigenic factors by tumour and tumour-associated stroma. However, on the other hand, they favoured recruitment of beneficial neutrophils through IL-8 secretion and, most importantly, they drove highly cytotoxic CCR5+CCR6+CD8+ T cells into tumour tissue, through CCL5 and CCL20 release.
27070705Colorectal CarcinomaInhibit immunity (T cell function)While two distinct subsets of myeloid cells induce an influx of T cells into the invasive margin via CXCL9/CXCL10, CCL5 is produced by these T cells and stimulates pro-tumoral effects via CCR5.
26406376Squamous Cell CarcinomaInhibit immunity (T cell function)Mechanistically, nuclear FAK is associated with chromatin and exists in complex with transcription factors and their upstream regulators that control Ccl5 expression. Finally, we show that a small-molecule FAK kinase inhibitor, VS-4718, which is currently in clinical development, also drives depletion of Tregs and promotes a CD8(+) T cell-mediated anti-tumor response.
26249173Breast CarcinomaInhibit immunityThus, our findings showed that CCL5/CCR3 signaling promotes metastasis by inducing Th2 polarization of CD4? T cells, with implications for prognosis and immunotherapy of luminal breast cancer.
25398437MelanomaPromote immunityHere we show how combining a senescence-inducing inhibitor of the mitotic kinase Aurora A (AURKA) with an MDM2 antagonist activates p53 in senescent tumors harboring wildtype 53. In the model studied, this effect is accompanied proliferation arrest, mitochondrial depolarization, apoptosis and immune clearance of cancer cells by antitumor leukocytes in a manner reliant upon CCL5, CCL1 and CXCL9.
25300859GliomaPromote immunitySTING contributes to antiglioma immunity via triggering type I IFN signals in the tumor microenvironment. Finally, intratumoral administration of a STING agonist (cyclic diguanylate monophosphate; c-di-GMP) improved the survival of glioma-bearing mice associated with enhanced type I IFN signaling, Cxcl10 and Ccl5, and T-cell migration into the brain.
27707838Breast CarcinomaPromote immunity (infiltration)We found that DDRD breast tumors were associated with CD4+ and CD8+ lymphocytic infiltration (Fisher's exact test P < .001) and that DDRD cells expressed the chemokines CXCL10 and CCL5 3.5- to 11.9-fold more than DNA damage response-proficient cells (P < .01).
29368981MelanomaPromote immunity (NK cell function); increase the efficacy of immunotherapySuch infiltration is primarily due to the ability of BECN1-defective tumor cells to overexpress and release CCL5 cytokine in the tumor microenvironment by a mechanism involving the activation of the MAPK8/JNK-JUN/c-Jun signaling pathway. Clinically, we reported a strong positive correlation between the expression of NK cell marker and CCL5 in human melanoma tumors and more importantly, a significant increased survival is found in melanoma patients expressing a high level of CCL5.
27407095Cervical carcinomaPromote immunityIntravaginal treatment of IL7-Fc, but not native IL7, induces upregulation of chemokines (CXCL10, CCL3, CCL4, and CCL5), cytokines (IFNγ, TNFα, IL6, and IL1β), and an adhesion molecule (VCAM-1) in the genital tract, leading to the recruitment of several leukocytes, including CD4, CD8, γδ T cells, and dendritic cells.
19602595Ovarian CarcinomaPromote immunity (T cell function)CCL5-mediated endogenous antitumor immunity elicited by adoptively transferred lymphocytes and dendritic cell depletion. Importantly, these shortly primed T cells secreted large amounts of CCL5, which was required for their therapeutic benefit. Accordingly, transferred T cells recruited CCR5(+) DCs into the tumor, where they showed distinct immunostimulatory attributes. Activated CCR5(+) host T cells with antitumor activity also accumulated at tumor locations, and endogenous tumor-specific memory T cells remained elevated after the disappearance of transferred lymphocytes.
28868628Ovarian CarcinomaInhibit immunity (T cell function)Ovarian cancer stem cells promote tumour immune privilege and invasion via CCL5 and regulatory T cells. The expression of its receptor, C-C motif chemokine receptor 5 (CCR5), was also increased on the surface of Tregs in ovarian cancer patients. This receptor-ligand expression profile indicated that ovarian CSCs recruit Tregs via CCL5-CCR5 interactions.
22282655Colorectal CarcinomaPromote immunity (infiltration); Inhibit immunity (T cell function)We found that higher levels of CCL5 expression in human and murine colon tumor cells correlated with higher levels of apoptosis of CD8+ T cells and infiltration of T-regulatory cells (T(reg)). We also found tumor growth to be diminished in mice lacking CCR5, a CCL5 receptor, where a similar decrease in both T(reg) cell infiltration and CD8(+) T-cell apoptosis was noted. TGF-β signaling blockade diminished apoptosis of CD8(+) T cells, implicating TGF-β as an effector of CCL5 action. In support of this concept, CCL5 failed to enhance the production of TGF-β by CCR5-deficient T(reg) or to enhance their cytotoxic effects against CD8(+) T cells.
28416485Triple-Negative Breast CarcinomaInhibit immunityWe demonstrate here that an autocrine CCL5-CCR5 axis is a major regulator of immunosuppressive myeloid cells (IMC) of both monocytic and granulocytic lineages. The absence of the autocrine CCL5 abrogated the generation of granulocytic myeloid-derived suppressor cells and tumor-associated macrophagesThe changes in the?ccl5-null myeloid compartment subsequently resulted in increased tumor-infiltrating cytotoxic CD8+?T cells and decreased regulatory T cells in tumor-draining lymph nodes. Targeting the host CCL5 in bone marrow via nanoparticle-delivered expression silencing, in combination with the CCR5 inhibitor Maraviroc, resulted in strong reductions of IMC and robust antitumor immunities.
19155524Pancreatic CarcinomaInhibit immunity (infiltration)When CCR5/CCL5 signaling is disrupted, either by reducing CCL5 production by tumor cells or by systemic administration of a CCR5 inhibitor (N,N-dimethyl-N-{{4-{[2-(4-methylphenyl)-6,7-dihydro-5H-benzocyclohepten-8-yl]carbonyl}amino}}benzyl]-N,N-dimethyl-N- {{{4-{{{[2-(4-methylphenyl)-6,7-dihydro-5H-benzocycloheptan-8-yl]carbonyl}amino}}benzyl}}}tetrahydro-2H-pyran-4-aminiumchloride; TAK-779), Treg migration to tumors is reduced and tumors are smaller than in control mice. Thus, this study demonstrates the importance of Tregs in immune evasion by tumors, how blockade of Treg migration might inhibit tumor growth, and, specifically in pancreatic adenocarcinoma, the role of CCR5 in the homing of tumor-associated Tregs.
29651051colon carcinomaInhibit immunityChemokine CCL5 was identified as a regulator of the T-cell immune response in the liver.
27991933Pancreatic Ductal AdenocarcinomaInhibit immunityFurthermore, CCL5 was directly trans-activated by cancer-FOXP3 and promoted the recruitment of Treg cells from peripheral blood to the tumor site in vitro and in vivo.
20400704Ovarian CarcinomaPromote immunityOur results unveil a therapeutic mechanism whereby tumor-primed CD4(+) T cells transferred into ovarian cancer-bearing mice secrete high levels of CCL5, which recruits endogenous CCR5(+) dendritic cells to tumor locations and activate them through CD40-CD40L interactions. These newly matured dendritic cells are then able to prime tumor-specific endogenous CD8(+) T cells, which mediate long-term protection.
25060519NeuroblastomaPromote immunityWhen used in combination, Ad5Δ24 directly accelerated the caspase pathways in tumor cells exposed to CAR-T cells, whereas the intratumoral release of both RANTES and IL15 attracted CAR-T cells and promoted their local survival, respectively, increasing the overall survival of tumor-bearing mice.
23266888Breast CarcinomaInhibit immunityBecause of the apparent dispensable nature of this molecule in normal physiology, CCL5 may represent an excellent therapeutic target in immunotherapy for breast cancer as well as a broad range of solid tumors that have significant amounts of MDSC infiltration. CCL5 also helps maintain the immunosuppressive capacity of human MDSCs.
Summary
SymbolCCL5
Namechemokine (C-C motif) ligand 5
Aliases RANTES; SISd; TCP228; MGC17164; T-cell specific protein p288; T-cell specific RANTES protein; SIS-delta; reg ......
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CCL5 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCCL5
Namechemokine (C-C motif) ligand 5
Aliases RANTES; SISd; TCP228; MGC17164; T-cell specific protein p288; T-cell specific RANTES protein; SIS-delta; reg ......
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CCL5 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.4820.478
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.3720.888
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.5670.784
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.3840.39
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.7960.541
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.1310.94
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.820.2
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.4740.303
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0320.984
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 4801
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 2801
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.490.0327
> Mutation difference between responders and non-responders
 

There is no record.
Summary
SymbolCCL5
Namechemokine (C-C motif) ligand 5
Aliases RANTES; SISd; TCP228; MGC17164; T-cell specific protein p288; T-cell specific RANTES protein; SIS-delta; reg ......
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CCL5. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCCL5
Namechemokine (C-C motif) ligand 5
Aliases RANTES; SISd; TCP228; MGC17164; T-cell specific protein p288; T-cell specific RANTES protein; SIS-delta; reg ......
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CCL5. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CCL5.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCCL5
Namechemokine (C-C motif) ligand 5
Aliases RANTES; SISd; TCP228; MGC17164; T-cell specific protein p288; T-cell specific RANTES protein; SIS-delta; reg ......
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CCL5. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCCL5
Namechemokine (C-C motif) ligand 5
Aliases RANTES; SISd; TCP228; MGC17164; T-cell specific protein p288; T-cell specific RANTES protein; SIS-delta; reg ......
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CCL5 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCCL5
Namechemokine (C-C motif) ligand 5
Aliases RANTES; SISd; TCP228; MGC17164; T-cell specific protein p288; T-cell specific RANTES protein; SIS-delta; reg ......
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CCL5 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCCL5
Namechemokine (C-C motif) ligand 5
Aliases RANTES; SISd; TCP228; MGC17164; T-cell specific protein p288; T-cell specific RANTES protein; SIS-delta; reg ......
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CCL5 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting CCL5.
ID Name Drug Type Targets #Targets
DB02322Heparin Disaccharide I-SSmall MoleculeCCL51
DB02353Heparin Disaccharide Iii-SSmall MoleculeCCL51